Point72 Asia Singapore Pte. Ltd. Sells 13,207 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Point72 Asia Singapore Pte. Ltd. cut its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 52.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,096 shares of the company’s stock after selling 13,207 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Ventyx Biosciences were worth $26,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Vestal Point Capital LP boosted its position in shares of Ventyx Biosciences by 31.2% during the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after buying an additional 410,000 shares during the period. Sio Capital Management LLC lifted its stake in Ventyx Biosciences by 153.2% in the 3rd quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after acquiring an additional 1,193,024 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Ventyx Biosciences by 3.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,101 shares of the company’s stock worth $1,058,000 after acquiring an additional 17,898 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Ventyx Biosciences during the 3rd quarter worth approximately $42,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Ventyx Biosciences by 10.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 462,170 shares of the company’s stock valued at $1,008,000 after purchasing an additional 42,600 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Stock Up 24.3 %

VTYX opened at $3.12 on Monday. The stock has a market cap of $220.62 million, a price-to-earnings ratio of -1.32 and a beta of 0.48. Ventyx Biosciences, Inc. has a 12-month low of $1.67 and a 12-month high of $11.48. The business has a 50 day moving average of $2.23 and a 200-day moving average of $2.51.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on VTYX shares. Wells Fargo & Company reduced their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Oppenheimer restated an “outperform” rating and issued a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Canaccord Genuity Group reduced their price target on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, November 11th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Insiders Place Their Bets

In related news, CEO Raju Mohan bought 261,752 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was bought at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the purchase, the chief executive officer now owns 2,175,028 shares in the company, valued at $4,371,806.28. This represents a 13.68 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 18.18% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.